Qualigen Therapeutics, Inc. — Director's Dealing 2020

Mar 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2020-03-04

Reporting Person: Ritter Andrew J (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-04	Common Stock	S	18750	$.3756	Disposed	81727	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	625	Direct

Footnotes

F1: As a managing partner of Stonehenge Partners LLC, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.